IV glibenclamide shows promise for reducing cerebral edema and appears to be safe. PO glyburide leads to more hypoglycemia, especially if abnl renal fxn. Smaller, more frequent dosing may help. Kudos to @MikeA_42 for pushing this through to publication. sciencedirect.com/science/articl…
Preclinical models show glibenclamide AKA glyburide inhibits Sur1, reduced cerebral edema, and improves neurological function pubmed.ncbi.nlm.nih.gov/24132564/
Retrospective study of patients with diabetes shows that those on sulfonylureas prior to their stroke had improved outcomes compared to those on other glycemic control agents. pubmed.ncbi.nlm.nih.gov/17673715/
The Games-RP trial led by @sheth_kevin and @wtkimberly showed that iv glibenclamide reduced cerebral edema and mortality attributed to edema, but did not achieve primary outcome (# of pts with good outcome without undergoing hemicrani).thelancet.com/journals/laneu…
Games-RP found no difference in hypoglycemia (glucose < 55.8 mg/dL) between groups (9% vs. 0%, p =.12). using IV glibenclamide infusion. There was no symptomatic hypoglycemia in the study.
In contrast, in our retrospective review of PO glyburide use (2.5 mg bid) we found that 23.9% of patients experienced hypoglycemia! Impaired renal function was the major risk factor while high BMI seemed protective.
Why the discrepancy? PO glyburide has narrow therapeutic index, highly variable bioavailability, and serum concentration depends on gastric pH which varies widely in ICU patients.
Does hypoglycemia matter? NICE-SUGAR trial showed aOR for death of 1.41 and 2.10 for moderate and severe hypoglycemia, respectively.nejm.org/doi/full/10.10…
Hypoglycemia could be even more injurious in brain injury where it is linked to brain energy crises and increased mortality.journals.lww.com/ccmjournal/Abs…
So be careful with po glyburide! If using, consider frequent glucose checks and smaller, more frequent doses (1.25mg q6h). Limit use in patients with renal dysfunction, low bmi, decrease in nutritional support.
CHARM study currently evaluating IV glibenclamide's effect on 90 day mRS after LHI. If positive study, perhaps we should all have access to IV formulation.clinicaltrials.gov/ct2/show/NCT02…